Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta‐analysis

Zaccardi, Francesco; Rocca, Bianca; Pitocco, Dario; Tanese, Luigi; Rizzi, Alessandro; Ghirlanda, Giovanni

doi:10.1002/dmrr.2625

Cited by 100 publications

(75 citation statements)

References 76 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The relation between MPV and DMT2 was first reported by Sharpe and Trinick who founded a significant increase of MPV in diabetic compared with non diabetic patients [41]. This research was followed by numerous studies and with largest study conducted on 13,021 diabetic patients [14,31,[42][43][44]. Similarly, Our study results had shown significantly higher MPV in the group B compared to the group A.…”

Section: Discussionsupporting

confidence: 74%

“…Platelets are a central element of the athero-thrombotic process due to their prothrombotic and proinflamatory function [8,9,10]. The association of increased MPV, PDW and decreased platelet count with disease related to endothelial dysfunction such as metabolic syndrome diabetes, coronary artery disease (CAD) and malignancy which has been shown in many studies [11][12][13][14][15]. Diabetes particularly DMT2 patients are exposed to the increased platelet reactivity due to multi factorial causes such as metabolic (e.g hyperglycemia, hypertriglyceridemia) and systemic abnormalities (eg.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of Mean Platelet Volume and Platelet Distribution Width with Hba1c

Jaman¹

2017

JED

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 74%

Section: Introductionmentioning

confidence: 99%

Association of Mean Platelet Volume and Platelet Distribution Width with Hba1c

Jaman¹

2017

JED

View full text Add to dashboard Cite

“…[5] The association of increased MPV, PDW, P-LCR, and platelet count with diseases related to endothelial dysfunction such as metabolic syndrome, diabetes, coronary artery disease (CAD), and malignancy has been shown in many studies. [6,7,8,9] The newer hematological analyzers are giving variety of platelet parameters which helps in easy detection of change in platelet structure, which may help in early detection of prothrombotic state of the platelets. These can act as an alarm for diagnosing initiation/progression of diabetic complications.…”

Section: Introductionmentioning

confidence: 99%

An Evaluation study of Platelet Volume Indices (PVI) in Type-2 Diabetes Mellitus and its Micro and Macro Vascular Complications

Desai¹,

Lakum

2018

APALM

View full text Add to dashboard Cite

Background:The study was performed to analyse PVI such as mean platelet volume (MPV), platelet distribution width (PDW) and plateletlarge cell ratio (P-LCR) that are useful for identifying large and haemostatically active platelets, which are risk factors for developing diabetes and its complication.Methods: Case-control study was conducted on 1026 Type 2 diabetics and 616 nondiabetics. Detailed clinical history regarding duration, hypertension and complications was taken. PVI was obtained using three part automated cell counter. Fasting blood glucose, hemoglobin A1C, lipid profile, creatinine were also obtained. Diabetics were further categorized into patients with complications and without complications.Result: MPV, PDW, P-LCR and platelet count were significantly increased in diabetic patients with complications as compared to diabetics without complications and nondiabetic group (P < 0.0001, < 0.0001, 0.0044, 0.023 respectively). We found statistically significant correlation between MPV and diabetic retinopathy (P < 0.0001), nephropathy (P = 0.04), neuropathy (P < 0.0001), coronary artery disease (P < 0.0001), diabetic foot (P = 0.005). PDW was statistically significantly increased in diabetic retinopathy (P < 0.0001), neuropathy (P < 0.0001), coronary artery disease (P < 0.0001), diabetic foot (P = 0.005). P-LCR was statistically significantly increased in diabetic retinopathy (P < 0.0001), neuropathy (P = 0.003), coronary artery disease (P < 0.0001), diabetic foot (P = 0.034). Conclusion:MPV, PDW and P-LCR are predictive biomarkers of diabetic vascular complications. They are more significant in microvascular complications than macrovascular complications.

show abstract

“…[74] This reduced insulin sensitivity increases platelet responsiveness to platelet activators, such as thrombin. [74] Platelets from patients with diabetes tend to have a larger mean platelet volume, [75][76][77] which allows the platelets to be more metabolically and enzymatically active [74]; thus, metabolism of arachidonic acid and subsequent production of TXA 2 are increased in platelets from patients with diabetes. [72][73][74]78] Larger platelets also contain more prothrombotic mediators and have a greater surface area over which to display adhesion molecules.…”

Section: Aspirin: Antiplatelet Effects and Pharmacokineticsmentioning

confidence: 99%

“…reduced production of TXA 2 ≥ 95%). [10,88] For example, the increased platelet turnover in patients with diabetes [75,76,85] combined with the short half-life of aspirin means that newly synthesized, hyper-reactive immature platelets remain uninhibited during a considerable portion of the 24-h window of time between once-daily aspirin doses. [11] Indeed, markers of immature platelets (i.e.…”

Section: Aspirin: Antiplatelet Effects and Pharmacokineticsmentioning

confidence: 99%

Aspirin in the prevention of cardiovascular events in patients with diabetes

Bell

2016

Postgraduate Medicine

View full text Add to dashboard Cite

Diabetes imparts a substantial increased risk for cardiovascular disease-related mortality and morbidity. Because of this, current medical guidelines recommend prophylactic treatment with once-daily, low-dose aspirin (acetylsalicylic acid) for primary and secondary prevention of cardiovascular (CV) events in high-risk patients. However, only modest reductions in CV events and mortality have been observed with once-daily aspirin treatment in patients with diabetes, including patients with a previous CV event, perhaps because of disparity between aspirin pharmacokinetics and diabetes-related platelet abnormalities. Once-daily aspirin irreversibly inactivates platelets for only a short duration (acetylsalicylic acid half-life, approximately 15-20 minutes), after which time newly generated, active platelets enter the circulation and weaken aspirin's effect. Platelets from patients with diabetes are more reactive and are turned over more rapidly than platelets from normal individuals; the short inhibitory window provided by once-daily aspirin may therefore be insufficient to provide 24-h protection against CV events. Alternative conventional aspirin regimens (e.g. higher daily dose, twice-daily dosing, combination with clopidogrel) and newer formulations (e.g. 24-h, extended-release) have been proposed to overcome the apparent limited efficacy of conventional aspirin in patients with diabetes; however, tolerability concerns and limited clinical efficacy data need to be taken into account when considering the use of such regimens. ARTICLE HISTORY

show abstract

Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta‐analysis

Cited by 100 publications

References 76 publications

Association of Mean Platelet Volume and Platelet Distribution Width with Hba1c

Association of Mean Platelet Volume and Platelet Distribution Width with Hba1c

An Evaluation study of Platelet Volume Indices (PVI) in Type-2 Diabetes Mellitus and its Micro and Macro Vascular Complications

Aspirin in the prevention of cardiovascular events in patients with diabetes

Contact Info

Product

Resources

About